These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 33131481)

  • 1. [Comparative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease].
    Gorbatenko VS; Gerasimenko AS; Shatalova OV
    Kardiologiia; 2020 Oct; 60(9):102-109. PubMed ID: 33131481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of off-label use of reduced-dose direct oral anticoagulants therapy in the treatment of pulmonary embolism comparable to standard-dose therapy.
    Yamazoe S; Imai H; Ogawa Y; Kano N; Murase Y; Mamiya K; Ikeda T; Hiramatsu K; Torii J; Kawaguchi K
    Heart Vessels; 2024 Apr; 39(4):365-372. PubMed ID: 38381170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulation for Atrial Fibrillation in Advanced CKD: Can Observational Studies Provide the Answer?
    Weiner DE; Sarnak MJ
    Am J Kidney Dis; 2024 Mar; 83(3):288-290. PubMed ID: 38231148
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety and efficacy of apixaban dosage for stroke prevention in atrial fibrillation with acute kidney injury populations in a tertiary care hospital.
    Kyaw KKK
    Clin Med (Lond); 2023 Nov; 23(Suppl 6):119-120. PubMed ID: 38182194
    [No Abstract]   [Full Text] [Related]  

  • 5. Stroke prevention in atrial fibrillation with chronic kidney disease: a delicate balance of efficacy and safety considerations.
    Barnes GD; Wright Nunes JA
    Res Pract Thromb Haemost; 2024 Feb; 8(2):102370. PubMed ID: 38666063
    [No Abstract]   [Full Text] [Related]  

  • 6. Twice- or Once-Daily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis.
    Mainbourg S; Cucherat M; Provencher S; Bertoletti L; Nony P; Gueyffier F; Mismetti P; Grange C; Durieu I; Kilo R; Laporte S; Grenet G; Lega JC;
    Thromb Res; 2021 Jan; 197():24-32. PubMed ID: 33161284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NOACs Added to WHO's Essential Medicines List: Recommendations for Future Policy Actions.
    Di Cesare M; Jarvis JD; Scarlatescu O; Leng X; Zaidel EJ; Burrone E; Eiselé JL; Prabhakaran D; Sliwa K
    Glob Heart; 2020 Oct; 15(1):67. PubMed ID: 33150132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Risk of Dementia With Direct Oral Anticoagulants Versus Warfarin Use in Patients With Non-valvular Atrial Fibrillation: A Systematic Review and Meta-analysis.
    Lee ZX; Ang E; Lim XT; Arain SJ
    J Cardiovasc Pharmacol; 2021 Jan; 77(1):22-31. PubMed ID: 33136766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants.
    Wallvik N; Renlund H; Själander A
    J Thromb Thrombolysis; 2021 Jul; 52(1):315-323. PubMed ID: 33140837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of anticoagulation therapy in atrial fibrillation: results from a large real-life single-center registry.
    Jurin I; Lucijanić M; Šakić Z; Hulak Karlak V; Atić A; Magličić A; Starčević B; Hadžibegović I
    Croat Med J; 2020 Oct; 61(5):440-449. PubMed ID: 33150762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of developing diabetes in patients with atrial fibrillation taking non-vitamin K antagonist oral anticoagulants or warfarin: A nationwide cohort study.
    Huang HK; Liu PP; Lin SM; Hsu JY; Peng CC; Munir KM; Wu TY; Yeh JI; Loh CH; Tu YK
    Diabetes Obes Metab; 2021 Feb; 23(2):499-507. PubMed ID: 33140538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective Review on the Safety and Efficacy of Direct Oral Anticoagulants Compared With Warfarin in Patients With Cirrhosis.
    Jones K; Pham C; Aguilar C; Sheth S
    Fed Pract; 2020 Oct; 37(10):479-485. PubMed ID: 33132687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dabigatran vs. Aspirin for Secondary Prevention After Embolic Stroke of Undetermined Source　- Japanese Subanalysis of the RE-SPECT ESUS Randomized Controlled Trial.
    Toyoda K; Uchiyama S; Hagihara Y; Kuwashiro T; Mori T; Kamiyama K; Urano Y; Taniguchi A; Nozaki K; Cronin L; Grauer C; Brueckmann M; Diener HC
    Circ J; 2020 Nov; 84(12):2286-2295. PubMed ID: 33132228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of antithrombotic agents for atrial fibrillation in older adults at risk for falls: a mathematical modelling study.
    Wong EKC; Belza C; Naimark DMJ; Straus SE; Wijeysundera HC
    CMAJ Open; 2020; 8(4):E706-E714. PubMed ID: 33158928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower dose direct oral anticoagulants and improved survival: A combined analysis in patients with established atherosclerosis.
    Cappato R; Chiarito M; Giustozzi M; Briani M; Ali H; Riva L; Bonitta G; Lodigiani C; Furlanello F; Balla C; Lupo P; Stefanini G
    Eur J Intern Med; 2021 Jan; 83():14-20. PubMed ID: 33158720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Atrial Fibrillation and Diabetes Mellitus: the Control of Thromboembolic Risk].
    Obrezan AG; Kulikov NV
    Kardiologiia; 2020 Aug; 60(7):108-114. PubMed ID: 33155949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and Treatment of Lower Extremity Venous Thromboembolism: A Review.
    Chopard R; Albertsen IE; Piazza G
    JAMA; 2020 Nov; 324(17):1765-1776. PubMed ID: 33141212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety.
    Hiatt WR; Bonaca MP; Patel MR; Nehler MR; Debus ES; Anand SS; Capell WH; Brackin T; Jaeger N; Hess CN; Pap AF; Berkowitz SD; Muehlhofer E; Haskell L; Brasil D; Madaric J; Sillesen H; Szalay D; Bauersachs R
    Circulation; 2020 Dec; 142(23):2219-2230. PubMed ID: 33138628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in the Prescription of Non-Vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation: Results of the Polish Atrial Fibrillation (POL-AF) Registry.
    Gorczyca I; Jelonek O; Uziębło-Życzkowska B; Chrapek M; Maciorowska M; Wójcik M; Błaszczyk R; Kapłon-Cieślicka A; Gawałko M; Budnik M; Tokarek T; Rajtar-Salwa R; Bil J; Wojewódzki M; Szpotowicz A; Bednarski J; Bakuła-Ostalska E; Tomaszuk-Kazberuk A; Szyszkowska A; Wełnicki M; Mamcarz A; Wożakowska-Kapłon B
    J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33167503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and safety of new oral anticoagulants as part of triple antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome. Data from an observational study].
    Sycheva NA; Koroleva LY; Nosov VP; Kovaleva GV; Paikova NN; Volkova AT; Kisel AM
    Kardiologiia; 2020 Aug; 60(7):53-63. PubMed ID: 33155941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.